<DOC>
	<DOCNO>NCT01850888</DOCNO>
	<brief_summary>This best available therapy/compassionate use single institution study design determine palliative benefit toxicity 131I-MIBG patient progressive neuroblastoma metastatic pheochromocytoma eligible therapy higher priority . Patients may receive range dos depend stem cell availability tumor involvement bone marrow . Response rate , toxicity , time progression death evaluate .</brief_summary>
	<brief_title>MIBG Refractory Neuroblastoma Pheochromocytoma</brief_title>
	<detailed_description>Primary Objective provide access therapy 131I-MIBG patient relapsed/refractory neuroblastoma metastatic pheochromocytoma . Secondary Objective ass disease response 131I-MIBG therapy patient relapsed/refractory neuroblastoma metastatic pheochromocytoma . Tertiary Objectives 1 ) gain information toxicity 131I-MIBG therapy ; 2 ) ass improvement symptom , include pain fatigue , patient relapsed/refractory neuroblastoma metastatic pheochromocytoma receive 131I-MIBG therapy . - The therapeutic dose 131I-MIBG base follow : 1 . Minimum dose 10 mCi/kg patient without stem cell source whose renal function upper limit normal still meet eligibility criterion . 2 . Dose 12 mCi/kg patient without stem cell source normal renal function meet eligibility criterion . 3 . Dose &gt; 12 mCi/kg 18 mCi/kg maximum investigator 's discretion patient meet eligibility criterion stem cell available . - A urinary catheter intravenous fluid use bladder protection , potassium iodide solution thyroid Protection . - G-CSF recommend patient ANC le 750 MIBG infusion . - hematopoietic stem cell infusion recommend patient grade 4 hematologic toxicity follow 131I-MIBG therapy continue ANC &lt; 200 G-CSF without sign recovery &gt; 2 week patient require platelet transfusion two time weekly 4 consecutive week . - Follow-up do disease progression , death therapy initiate .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Diagnosis : Relapsed/refractory neuroblastoma original diagnosis base tumor histopathology elevate urine catecholamine typical neuroblastoma cell bone marrow Metastatic pheochromocytoma Age &gt; 1 year able cooperate radiation safety restriction therapy period Karnofsky Lansky performance status ≥ 50 % Life expectancy : ≥ least 8 week Disease status : Failure respond standard therapy development progressive disease time . Disease must evaluable MIBG scan . A positive MIBG scan must present within 8 week prior study entry subsequent intervening therapy . If patient one MIBG positive lesion lesion radiate , biopsy must do least 4 week radiation complete must show viable neuroblastoma . Stem Cells : Patients must hematopoietic stem cell product available reinfusion MIBG treatment dose &gt; 12 mCi/kg . Have acceptable organ function define within 7 day enrollment : Bone Marrow : ANC ≥750 X 109 /L platelet ≥50,000 X 109 /L without transfusion stem cell available ( ANC platelet allow stem cell available ) Renal : Creatinine ≤3x upper limit normal Hepatic : Bilirubin ≤2x upper limit normal ; AST/ALT ≤10x upper limit normal Cardiac : Ejection fraction ≥45 % echocardiogram Pulmonary : normal lung function manifest dyspnea and/or oxygen saturation ≥ 88 % room air . Prior Therapy : Patients must recover acute toxicity ( define CTCAE 4.0 ≤ grade 1 ) associate prior therapy , : Myelosuppressive chemotherapy : At least 2 week elapse since chemotherapy cause myelosuppression Biologic ( antineoplastic agent ) : At least 7 day elapse since completion therapy biologic agent . Monoclonal antibody : At least 3 halflives elapse since therapy monoclonal antibody Radiation therapy : Threemonths elapse case complete radiation follow field : craniospinal , total abdominal , whole lung , total body irradiation ) . For site radiation , least 2 week relapse . Cytokine therapy ( e.g . GCSF , GMCSF , IL6 , IL2 ) : must discontinue minimum 24 hour prior MIBG therapy . Voluntary write informed consent Patients disease major organ system would compromise ability withstand therapy . Because teratogenic potential study medication , patient pregnant lactate allow . Patients childbearing potential must practice effective method birth control participate study , avoid possible damage fetus . Known allergy agent ingredient use study . Patients hemodialysis Patients untreated positive blood culture progressive infection assess radiographic study</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>neuroblastoma</keyword>
	<keyword>pheochromocytoma</keyword>
</DOC>